Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2028

Conditions
Aortic DissectionInflammation
Interventions
DRUG

Ketorolac

patients in the experimental group will receive ketorolac treatment for Stanford Type A aortic dissection, consisting of a 60mg intramuscular injection preoperatively followed by 30mg twice daily for two days postoperatively, while maintaining standard baseline therapies including analgesia, blood pressure control, and subsequent cardiovascular surgical management.

DRUG

0.9 % saline

0.9% saline

Trial Locations (1)

210008

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
collaborator

Guangdong Provincial People's Hospital

OTHER

collaborator

Huai'an First People's Hospital

OTHER

collaborator

Shandong Provincial Hospital

OTHER_GOV

collaborator

First Affiliated Hospital of Harbin Medical University

OTHER

collaborator

The Second Affiliated Hospital of Harbin Medical University

OTHER

collaborator

THE FIRST AFFILIATED HOSPITAL OF SHIHEZI UNIVERSITY

UNKNOWN

collaborator

Xinhua Hospital of Ili Kazak Autonomous Prefecture

UNKNOWN

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER